[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1996

Expression of Interleukin-4 in Scleroderma Skin Specimens and Scleroderma Fibroblast CulturesPotential Role in Fibrosis

Author Affiliations

From the Laboratoire de Recherche Biomédicale en Dermatologie (Drs Salmon-Ehr, Serpier, and Kalis), the Laboratoire de Biochimie Médicale et Biologie Moléculaire—Centre National de la Recherche Scientifique (CNRS EP 89) (Drs Gillery, Maquart, Salmon-Ehr, and Serpier), and the Institut National de la Santé et de la Recherche Médicale Unité 314 (Ms Nawrocki and Drs Clavel and Birembaut), School of Medicine, University of Reims Champagne-Ardenne, Reims, France.

Arch Dermatol. 1996;132(7):802-806. doi:10.1001/archderm.1996.03890310088013
Abstract

Background:  Scleroderma (systemic sclerosis) is a fibrotic disease characterized by an uncontrolled tissular accumulation of collagen. Several cytokines have been implicated in the fibroblast activation leading to fibrosis. For instance, we have previously demonstrated that interleukin-4 (IL-4) is a potent activator of collagen synthesis in fibroblast cultures. In this study, using immunocytochemical methods and in situ hybridization, we investigated the expression of IL-4 in normal and scleroderma skin and fibroblast cultures.

Observations:  Immunocytochemical studies with anti—IL-4 antibody were performed on biopsy specimens from 9 patients with normal skin and 11 patients with scleroderma. The label was intense or strong in 8 of the 11 scleroderma skin specimens, whereas it was negative or faint in 8 of the 9 normal skin specimens (P<.01). In situ hybridization demonstrated a significant increase of the number of IL-4 messenger RNA grains in scleroderma skin compared with normal skin (3.1± 1.5 [mean±SD] vs 0.8±0.7; P<.001). A strongly positive labeling with the anti—IL-4 antibody was found in the 4 scleroderma fibroblast cultures, whereas it was negative in the 5 fibroblast control cultures (P<.05).

Conclusions:  Our results demonstrate that IL-4 is strongly expressed in the dermis of a large majority of patients with scleroderma and might be synthesized by scleroderma fibroblasts. We suggest that IL-4 is one of the cytokines implicated in the early steps of the fibrotic process.Arch Dermatol. 1996;132:802-806

×